POMDOCTOR LIMITED Announces Receipt of Nasdaq Notice

Rhea-AI Summary

POMDOCTOR LIMITED (NASDAQ: POM) received a Nasdaq Deficiency Letter dated Jan 29, 2026, reporting the ADS closing bid price was below the required $1.00 minimum for 33 consecutive business days. The letter currently does not affect listing or trading.

The company has a 180-calendar-day compliance period ending July 28, 2026 to regain compliance by achieving a $1.00 closing bid for 10 consecutive business days; Nasdaq may grant additional time at its discretion.

Positive

• ADSs remain listed and tradable while the Deficiency Letter has no current effect
• Company granted a 180-calendar-day compliance period through July 28, 2026
• Regain condition clearly defined: $1.00 closing bid for 10 consecutive business days

Negative

• Closing bid below $1.00 for 33 consecutive business days
• Company faces potential Nasdaq compliance risk if not regained by July 28, 2026
• Possible further review or delisting proceedings if Nasdaq does not grant additional time

Market Reaction

+6.45% $0.25

15m delay 1 alert

+6.45% Since News

$0.25 Last Price

$0.22 $0.25 Day Range

+$2M Valuation Impact

$28M Market Cap

0.0x Rel. Volume

Following this news, POM has gained 6.45%, reflecting a notable positive market reaction. The stock is currently trading at $0.25. This price movement has added approximately $2M to the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Non-compliance days: 33 consecutive business days Nasdaq minimum bid price: US$1.00 per share Initial compliance period: 180 calendar days +5 more

8 metrics

Non-compliance days 33 consecutive business days Closing bid below US$1.00 requirement

Nasdaq minimum bid price US$1.00 per share Nasdaq Listing Rule 5450(a)(1)

Initial compliance period 180 calendar days Compliance period ending July 28, 2026

Compliance deadline July 28, 2026 End of initial Nasdaq bid price compliance period

Required bid-price streak 10 consecutive business days Minimum period at or above US$1.00 to regain compliance

Current price US$0.2311 Before announcement; at 52-week low and below US$1.00

52-week high US$6.43 Price is substantially below prior 12-month peak

Market cap US$26,365,837 Equity value prior to Nasdaq notice

Market Reality Check

Price: $0.2311 Vol: Volume 351,189 is at 0.76...

normal vol

$0.2311 Last Close

Volume Volume 351,189 is at 0.76x its 20-day average of 463,418 shares. normal

Technical Price 0.2311 is trading below the 200-day MA of 1.1 and at its 52-week low.

Historical Context

4 past events · Latest: Jan 16 (Positive)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Jan 16	Strategic partnerships	Positive	-1.7%	Strengthened collaborations with domestic pharma firms for internet hospital growth.
Dec 03	Earnings update	Positive	+5.4%	First-half 2025 results with revenue and gross profit growth despite net loss.
Oct 10	Overallotment exercise	Positive	+1.1%	Full exercise of underwriter’s option to buy additional ADSs at IPO price.
Oct 09	IPO completion	Positive	+18.4%	Closing of initial public offering of ADSs on Nasdaq Global Market.

Pattern Detected

Most prior corporate and financing announcements saw price moves align with the news tone, though the recent strategic partnership update drew a modestly negative reaction despite constructive language.

Recent Company History

Over the past few months, Pomdoctor listed on Nasdaq and completed its IPO, including full exercise of the underwriter’s over-allotment, raising gross proceeds of about $23,000,016. Subsequent earnings for the first half of fiscal 2025 showed 16.2% net revenue growth and continued net losses, while cash remained limited. A January 2026-01-16 update emphasized deepening partnerships with pharmaceutical companies to grow its internet hospital business. Today’s Nasdaq minimum-bid-price deficiency notice follows this trajectory of operational progress alongside significant share price pressure.

Market Pulse Summary

The stock is up +6.5% following this news. A strong positive reaction aligns with a pattern where mo...

Analysis

The stock is up +6.5% following this news. A strong positive reaction aligns with a pattern where most prior corporate milestones, such as the IPO and over-allotment exercise, saw price moves track the generally positive tone. However, today’s Nasdaq minimum-bid-price deficiency notice highlights that the stock traded at just US$0.2311, far below the US$1.00 threshold and its prior US$6.43 high. Investors would need to weigh any upside move against ongoing listing risk and the company’s recent history of net losses.

Key Terms

american depositary shares, nasdaq listing rule 5450(a)(1), minimum bid price, compliance period

4 terms

american depositary shares financial

"the closing bid price of the Company's American depositary shares (the "ADSs")"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

nasdaq listing rule 5450(a)(1) regulatory

"minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5450(a)(1)"

Nasdaq Listing Rule 5450(a)(1) is a continued-listing standard that sets a minimum share price companies must maintain to remain listed on the Nasdaq market—commonly a $1.00 per-share threshold. Investors care because falling below that floor can trigger a compliance review and possible delisting, which is like failing a minimum grade and losing access to the public market; delisting can reduce liquidity, visibility and the ability to raise capital.

minimum bid price regulatory

"was below the minimum bid price of US$1.00 per share requirement"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

compliance period regulatory

"provided with a compliance period of 180 calendar days, or until July 28, 2026"

A compliance period is a defined stretch of time during which a company must meet specific legal, regulatory, or contractual rules and reporting requirements. Think of it like a scheduled inspection window or a homework deadline: failing to satisfy the rules within that window can trigger fines, restrictions, or extra oversight, so investors watch compliance periods as signals of near-term legal risk, potential costs, and impacts on a company’s operations or cash flow.

AI-generated analysis. Not financial advice.

GUANGZHOU, China, Feb. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that it has received a written notification (the "Deficiency Letter") from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated January 29, 2026, indicating that for the last 33 consecutive business days, the closing bid price of the Company's American depositary shares (the "ADSs") was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Deficiency Letter has no current effect on the listing or trading of the Company's ADSs on Nasdaq.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days, or until July 28, 2026 (the "Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price of the Company's ADSs is at least US$1.00 for a minimum of ten consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.

In the event the Company does not regain compliance by July 28, 2026, subject to the determination by the staff of Nasdaq, the Company may be eligible for additional time.

The Deficiency Letter will have no effect on the Company's business operations, and the Company will take all reasonable measures to regain compliance.

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-receipt-of-nasdaq-notice-302674985.html

SOURCE POMDOCTOR LIMITED

FAQ

What did POM announce about the Nasdaq Deficiency Letter on February 2, 2026?

POM announced it received a Nasdaq Deficiency Letter after 33 consecutive business days below $1.00. According to the company, the letter currently does not affect listing or trading and identifies the minimum bid price deficiency.

How long does POM have to regain Nasdaq compliance (symbol POM)?

POM has a 180-calendar-day compliance period ending July 28, 2026 to regain the minimum bid price. According to the company, Nasdaq may grant additional time at its discretion if criteria are not met.

What is the requirement for POM to regain Nasdaq compliance?

To regain compliance POM must have the ADS closing bid at least $1.00 for 10 consecutive business days. According to the company, Nasdaq will confirm compliance in writing once this condition is met.

Does the Nasdaq Deficiency Letter affect POM’s trading or operations now?

The Deficiency Letter has no current effect on POM’s listing or trading on Nasdaq. According to the company, the letter does not impact its business operations and it will pursue measures to regain compliance.

What happens if POM does not regain compliance by July 28, 2026?

If POM does not regain compliance by July 28, 2026, Nasdaq may determine eligibility for additional time or begin delisting procedures. According to the company, any additional time is subject to Nasdaq staff determination.